List of Vaccines Companies in Norway - 6

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in-class enzyme technologies to commercial partners who develop therapeutics, in vitro diagnostics, and molecular research kit products. Our mission is to make our customers lives easier by unlocking new solutions to enhance quality of life and create a more sustainable healthy world. We provide our customers with cold-adapted enzymes from the arctic environment with unique features including heat lability and activity in challenging environments, as well as, customised engineered novel features which can be easily integrated to fuel their innovations. For more information, please visit www.arcticzymes.com

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in-class enzyme technologies to commercial partners who develop therapeutics, in vitro diagnostics, and molecular research kit products. Our mission is to make our customers lives easier by unlocking new solutions to enhance quality of life and create a more sustainable healthy world. We provide our customers with cold-adapted enzymes from the arctic environment with unique features including heat lability and activity in challenging environments, as well as, customised engineered novel features which can be easily integrated to fuel their innovations. For more information, please visit www.arcticzymes.com

Bionor Holding is a privately held biopharmaceutical company focused on advancing its proprietary therapeutic vaccines toward HIV cure.

Circio Holding ASA is a clinical stage company developing immune activators to target difficult-to-treat diseases. The company’s mission is to deploy vector-based technology to create a novel class of targeted, multi-functional circRNA medicines. It has established a cutting-edge circular RNA (circRNA) program and is collaborating with Prof Michael Uhlin and a team at the Karolinska Institutet in Stockholm with the intent to develop next generation RNA therapeutics for various applications. The company also has a mutant RAS cancer vaccine program, with two collaborative clinical trials underway in the USA and Norway. It is currently looking at options for the financing of a phase 2 study for ONCOS-102, a genetically modified oncolytic adenovirus.

We are a leading technology platform that unlocks unlimited possibilities for the future of medicine through our intelligent modular design and tailored hyper targeting.

PCI Biotech is a biopharmaceutical clinical stage development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that is used to unlock the true potential of therapeutic modalities. The company’s lead programme fimaVACC aims to enhance immunotherapy in cancer, by triggered endosomal release of antigens or nucleic acids encoding antigens, or immunostimulatory factors. Enhancement of relevant immune responses with protein- and peptide-based vaccines were successfully demonstrated in humans through an extensive Phase I study in healthy volunteers and a Phase II study is in planning with the aim to demonstrate enhancement of immunotherapy for treatment of solid tumours. In the fimaNAC programme endosomal release is utilised to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field. For further information, please visit: www.pcibiotech.com Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo PCI Biotech was established 2000 and is since June 2008 listed on the Oslo Børs. The company is headquartered in Oslo, Norway.